Fintel on MSN11h
Maxim Group Upgrades Moleculin Biotech (MBRX)Fintel reports that on March 25, 2025, Maxim Group upgraded their outlook for Moleculin Biotech (NasdaqCM:MBRX) from Hold to ...
Maxim Group analyst Tate Sullivan maintained a Hold rating on Nxu (NXU – Research Report) yesterday. The company’s shares closed yesterday at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback